A new trading day began on Friday, with Neogenomics Inc. (NASDAQ: NEO) stock price up 3.97% from the previous day of trading, before settling in for the closing price of $13.34. NEO’s price has ranged from $11.03 to $21.22 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 17.35% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 117.78%. With a float of $126.12 million, this company’s outstanding shares have now reached $127.37 million.
In an organization with 2100 employees, it is important to assess its efficiency.
Neogenomics Inc. (NEO) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Diagnostics & Research Industry. The insider ownership of Neogenomics Inc. is 1.25%, while institutional ownership is 100.50%. The most recent insider transaction that took place on May 15 ’24, was worth 16,511. In this transaction General Counsel of this company sold 1,049 shares at a rate of $15.74, taking the stock ownership to the 44,867 shares. Before that another transaction happened on Mar 04 ’24, when Company’s Director sold 6,112 for $15.97, making the entire transaction worth $97,579. This insider now owns 50,062 shares in total.
Neogenomics Inc. (NEO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 117.78% per share during the next fiscal year.
Neogenomics Inc. (NASDAQ: NEO) Trading Performance Indicators
Here are Neogenomics Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.67, a number that is poised to hit -0.00 in the next quarter and is forecasted to reach 0.16 in one year’s time.
Technical Analysis of Neogenomics Inc. (NEO)
Let’s dig in a bit further. During the last 5-days, its volume was 0.79 million. That was inferior than the volume of 0.85 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 60.76%. Additionally, its Average True Range was 0.47.
During the past 100 days, Neogenomics Inc.’s (NEO) raw stochastic average was set at 23.22%, which indicates a significant decrease from 68.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.88% in the past 14 days, which was lower than the 46.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.08, while its 200-day Moving Average is $15.16. However, in the short run, Neogenomics Inc.’s stock first resistance to watch stands at $14.16. Second resistance stands at $14.45. The third major resistance level sits at $14.89. If the price goes on to break the first support level at $13.43, it is likely to go to the next support level at $12.99. Assuming the price breaks the second support level, the third support level stands at $12.70.
Neogenomics Inc. (NASDAQ: NEO) Key Stats
With a market capitalization of 1.77 billion, the company has a total of 127,712K Shares Outstanding. Currently, annual sales are 591,640 K while annual income is -87,970 K. The company’s previous quarter sales were 156,240 K while its latest quarter income was -27,060 K.
